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Abstract Imaging is a crucial part of the evaluation of
children with primary liver malignancies. In addition to
staging the intrahepatic extent of the tumour, the 2005 revision
of the PRETEXT system specifies certain criteria for
assessment of extrahepatic disease. This article reviews the
imaging findings of two of these criteria: direct extrahepatic
extension of the tumour (E1, E1a, E2, E2a) and tumour
rupture at diagnosis (H1).
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Introduction
There are two main staging systems for primary malignant
liver tumours of childhood. The system used by the
Children’s Oncology Group, predominantly in North
America, is based mainly on the surgical findings and
extent of resection of the tumour, and is most appropriate
for use in treatment protocols that favour immediate surgery
at diagnosis [1, 2]. In contrast, the PRETEXT system is
designed to evaluate tumours regardless of whether primary
surgery is performed, and is used by the International
Childhood Liver Tumor Strategy Group (SIOPEL) [3].
With increasing experience and international cooperation it
has become clear that each system has its own merits, and
the two are not mutually exclusive. The PRETEXT system
is likely to be used for the purpose of making comparisons
between trials conducted by different groups.
Various criteria for assessment of vascular invasion and
extrahepatic spread of tumour are important parts of the
2005 revision of the PRETEXT system [3]. Different forms
of extrahepatic tumour spread are distinguished, according
to whether they involve direct extension or peritoneal
disease (E1, E1a, E2, E2a), tumour rupture at diagnosis
(H1), lymph node metastasis (N1, N2), or other forms of
metastasis (M1).
Although the PRETEXT system can be used to stage any
primary liver tumour, it is most often used in hepatoblas-
toma, which is the most common primary malignant liver
tumour of childhood, even in areas where the prevalence of
hepatitis B is high [4, 5]. In the current SIOPEL system, the
presence of any of the criteria E1, E1a, E2, E2a, H1, M1,
N1 or N2 in a child with hepatoblastoma mandates
treatment on a high-risk protocol. Although the new
Children’s Oncology Group protocol for treatment of
hepatoblastoma is not finalized, it will probably also rely
to a large extent on imaging for risk stratification. The
identification of these forms of spread is therefore crucial to
accurate patient management.
This article reviews the imaging findings of direct
tumour extension and peritoneal disease (E1, E1a, E2,
E2a) and tumour rupture at diagnosis (H1). The technical
aspects of imaging liver tumours in children have recently
been reviewed by Roebuck et al. [6].
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Extrahepatic abdominal disease (E1, E1a, E2, E2a)
In the SIOPEL 3 study, 17 (4.1%) of 417 patients with
hepatoblastoma registered before the end of 2004 were
classified as E+ (M. Childs, personal communication). The
original PRETEXT system, which was used in this study,
included patients with lymph node metastases in this group.
This indicates that direct extension of tumour, as detected
by imaging findings at diagnosis, is clearly very uncommon
in hepatoblastoma. Isolated extrahepatic spread is even less
common: only 6 of the 17 patients (1.4% of those with
hepatoblastoma) were classified as high risk on this basis
alone. As a consequence, until the 2005 revision of the
PRETEXT system, all SIOPEL protocols required that
extrahepatic abdominal spread of tumour (E+), including
lymph node metastases, be proved by biopsy. It was
unfortunate that this rule failed to distinguish between
different tumour types. A second problem was that some
types of direct tumour spread (through the diaphragm, for
example) are difficult to biopsy safely. In addition, the
requirement for biopsy proof prevented the full use of the
emerging capabilities of modern imaging techniques.
In the revised system, two stages of intra-abdominal
spread are recognized. In the first, E1, there is direct growth
of tumour into adjacent structures. This must be distin-
guished from an exophytic tumour growth pattern. In fact,
hepatoblastoma often grows in a pedunculated manner, and
when there is no unequivocal evidence of invasion of
adjacent structures, tumours of this type are regarded as
being confined to the liver [3].
In principle, the tumour may grow into any of the
structures that are anatomically related to the liver.
Fig. 1 Extension of hepatoblastoma through the diaphragm (E1).
Contrast-enhanced CT at two levels shows growth of the primary
tumour through the diaphragm into the thorax
Fig. 2 Extension of hepatoblastoma into the hepatic flexure of the
colon (E1). a Transverse MR image shows extension of a tumour
arising in segment 6 of the liver (white arrows) into the colon (red
arrows). b At surgery, the hepatic flexure was densely adherent to the
liver, and the right lobe and this section of bowel were resected en
bloc. Histological sections revealed direct invasion of the bowel wall.
The photomicrograph demonstrates colonic mucosa on the right with
underlying submucosal tumour showing marked chemotherapy-asso-
ciated change. There is puckering of the muscularis mucosae,
indicating previous involvement by viable locally invasive tumour at
this point (H&E, original magnification x40). The patient had suffered
episodes of gastrointestinal bleeding
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Although it is uncommon in hepatoblastoma, about 10% of
adults with hepatocellular carcinoma have diaphragmatic
adhesion or invasion by tumour [7]. At the time the original
PRETEXT system was devised, there was no good
preoperative method for assessing involvement of the
diaphragm [7]. Diaphragmatic penetration by tumour may
now be shown convincingly by MRI or CT (Fig. 1).
Coronal or sagittal images may be more helpful than
transverse images in this context. Subtle diaphragmatic
invasion and tumour adhesion to the diaphragm without
tumour invasion will be missed at cross-sectional imaging.
Invasion of the duodenum or colon (Fig. 2) appears to be
quite rare in both hepatoblastoma and hepatocellular carci-
noma, although there is little published information on this
subject. There may also be direct extension of tumour into
the retroperitoneum, with involvement of the pancreas
(Fig. 3). When this occurs, the alternative diagnosis of
pancreatoblastoma (another tumour that may secrete alpha-
fetoprotein) with liver involvement should be considered.
Peritoneal spread of tumour is also unusual in children, but
may be shown by cross-sectional imaging (Figs. 4 and 5).
Ultrasonography is particularly sensitive in the detection of
small peritoneal implants in the presence of ascites. It seems
intuitively likely that this form of spread is prognostically
worse than direct extension, and for this reason the 2005
revision defines peritoneal implants as E2. Biopsy proof is
not required if the imaging findings are diagnostic.
In current SIOPEL protocols, children with hepatoblas-
toma and either E1 or E2 are assigned to the high-risk
treatment group. This allocation is arbitrary, because there
is so far no evidence from any large study that extrahepatic
abdominal spread is an independent risk factor. All patients
without evidence of E1 or E2 are coded as E0. Abdominal
lymph node metastases are considered separately in the
2005 revision [3].
It is not known whether ascites, which is seen at
presentation in a minority of children with primary liver
tumours, is a marker of poor prognosis. The suffix “a” is
added to the E number of patients with ascites (i.e. E0a,
E1a or E2a as appropriate) in order to facilitate prospective
analysis of its significance [3].
Tumour rupture (intraperitoneal haemorrhage)
at diagnosis (H1)
Tumour rupture (Fig. 6) is a well-recognized presentation of
both hepatoblastoma and hepatocellular carcinoma in
childhood [8–10]. Its prognostic significance is not certain,
but since the opening of the SIOPEL 4 study in September
Fig. 3 Retroperitoneal extension in a patient with small-cell undif-
ferentiated hepatoblastoma (E1). a CT shows a large PRETEXT III
tumour with displacement of the right branch of the portal vein
(arrow) and retroperitoneal extension (E1). b Image at a more caudal
level shows involvement of the caudate lobe (C1), encasement of the
main portal vein (P2) and direct extension into the pancreas (E1)
Fig. 4 Peritoneal tumour seeding in a child with hepatoblastoma (E2).
US image shows peritoneal nodules (arrows). The diagnosis was
confirmed by biopsy
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2004, tumour rupture (H1) has become a defining feature of
high-risk hepatoblastoma in SIOPEL studies. It should be
noted that characteristic imaging and clinical findings (such
as hypotension and low haematocrit or haemoglobin level)
are regarded as sufficient to make this diagnosis. Para-
centesis is not recommended unless there is any clinical
doubt. Embolization may be appropriate if there is continu-
ing haemorrhage [11–13]. Localized or subcapsular haem-
orrhage (Fig. 7) is a fairly common finding and is
specifically excluded from H1, as is biopsy-related intra-
peritoneal bleeding. Patients with no evidence of tumour
rupture or haemorrhage are coded as H0 [3].
Fig. 6 Tumour rupture in a patient with newly diagnosed hepato-
blastoma (H1). Coronal CT image shows high attenuation intraperi-
toneal fluid compatible with blood over the surface of the right lobe of
the liver (arrows)
Fig. 7 Subcapsular haemorrhage in a patient with hepatoblastoma
(H0). CT shows a thin crescent of fluid over the lateral surface of the
right lobe (arrows). This is a common finding and does not affect
staging
Fig. 5 Peritoneal tumour nodules and ascites in a child with
multifocal hepatoblastoma (E2a). a CT shows peritoneal nodules
(arrows). b Coronal MRI (HASTE sequence) shows nodules (arrows)
with surrounding ascites
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